DK349481A - Enzyminhibitorer - Google Patents

Enzyminhibitorer

Info

Publication number
DK349481A
DK349481A DK349481A DK349481A DK349481A DK 349481 A DK349481 A DK 349481A DK 349481 A DK349481 A DK 349481A DK 349481 A DK349481 A DK 349481A DK 349481 A DK349481 A DK 349481A
Authority
DK
Denmark
Prior art keywords
enzyme inhibitors
inhibitors
enzyme
Prior art date
Application number
DK349481A
Other languages
English (en)
Inventor
M Szelke
D M Jones
A Hallett
Original Assignee
Ferring Pharmaceutticals
Farring Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Pharmaceutticals, Farring Ab filed Critical Ferring Pharmaceutticals
Publication of DK349481A publication Critical patent/DK349481A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK349481A 1980-08-06 1981-08-06 Enzyminhibitorer DK349481A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8025579 1980-08-06
GB8118194 1981-06-12

Publications (1)

Publication Number Publication Date
DK349481A true DK349481A (da) 1982-02-07

Family

ID=26276457

Family Applications (1)

Application Number Title Priority Date Filing Date
DK349481A DK349481A (da) 1980-08-06 1981-08-06 Enzyminhibitorer

Country Status (9)

Country Link
US (1) US4424207A (da)
EP (1) EP0045665B1 (da)
AU (1) AU549157B2 (da)
DE (1) DE3172138D1 (da)
DK (1) DK349481A (da)
ES (1) ES504575A0 (da)
FI (1) FI812427L (da)
IE (1) IE51471B1 (da)
NO (1) NO812612L (da)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609643A (en) * 1980-08-06 1986-09-02 Aktiebolaget Hassle Renin inhibitors, treatments and dipeptide synthesis
DE3377497D1 (en) * 1982-09-15 1988-09-01 Haessle Ab Enzyme inhibitors
US4650661A (en) * 1982-09-15 1987-03-17 Aktiebolaget Hassle Enzyme inhibitors
US4595677A (en) * 1982-12-03 1986-06-17 Ciba-Geigy Corporation Substituted tetrapeptides
GB2135773B (en) * 1983-01-31 1985-12-04 Boots Celltech Diagnostics Enzyme inhibitor labelled immunoassay
FI843837A0 (fi) * 1983-02-07 1984-09-28 Ferring Ab Enzyminhibitorer.
GB8322414D0 (en) * 1983-08-19 1983-09-21 Szelke M Renin inhibitors
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
IT1164239B (it) * 1983-05-25 1987-04-08 Anic Spa Un retro-inverso analogo del decapeptide (5-14)dell'angiotensinogeno equino inibitore specifico della renina con elevata resistenza all'idrolisi enzimatica
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
EP0144290A3 (de) * 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
JPS60163899A (ja) * 1984-02-03 1985-08-26 Sankyo Co Ltd レニン阻害ペプチド類
FI850948A7 (fi) 1984-03-12 1985-09-13 Pfizer Reniinin inhibitoreja, jotka sisältävät statiinia tai sen johdannaisia.
US4668663A (en) * 1984-03-27 1987-05-26 Merck & Co., Inc. Renin inhibitors containing homophe8
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
EP0156318A3 (en) * 1984-03-27 1988-07-06 Merck & Co. Inc. C-terminal amide cyclic renin inhibitors containing peptide isosteres
US4663310A (en) * 1984-04-04 1987-05-05 Merck & Co., Inc. Renin inhibitors containing 2-substituted statine
EP0163237A3 (en) * 1984-05-29 1988-04-27 Merck & Co. Inc. Di- and tri-peptidal renin inhibitors
US4645759A (en) * 1984-06-22 1987-02-24 Abbott Laboratories Renin inhibiting compounds
US4652551A (en) * 1984-06-22 1987-03-24 Abbott Laboratories Renin inhibiting compounds
US4880781A (en) * 1984-08-06 1989-11-14 The Upjohn Company Renin inhibitory peptides containing an N-alkyl-histidine moiety
DK356085A (da) * 1984-08-06 1986-02-07 Upjohn Co Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
DE3438545A1 (de) * 1984-10-20 1986-04-24 Merck Patent Gmbh, 6100 Darmstadt Peptide
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
DE3512128A1 (de) 1985-04-03 1986-10-09 Merck Patent Gmbh, 6100 Darmstadt Peptide
US4882420A (en) * 1985-04-19 1989-11-21 The Upjohn Company Dihalo-statine substituted renin inhibitors
WO1986006379A1 (en) 1985-04-19 1986-11-06 The Upjohn Company Dihalo-statine substituted renin inhibitors
US4826815A (en) * 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
US4665055A (en) * 1985-06-17 1987-05-12 Merck & Co., Inc. Peptide renin inhibitors
US4777286A (en) * 1985-06-18 1988-10-11 The Upjohn Company Certain aryl or hetero-hydroxamic acid esters useful as renin inhibitors
US4992562A (en) * 1985-08-09 1991-02-12 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US4729985A (en) 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US4906613A (en) * 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
DE3540495A1 (de) * 1985-11-15 1987-05-21 Merck Patent Gmbh Aminosaeurederivate
EP0258289A4 (en) * 1986-01-16 1991-01-02 Joseph Dellaria Peptide analogs
FI870474A7 (fi) * 1986-02-07 1987-08-08 Ciba Geigy Ag Med svavelhaltiga grupper substituerade 5-amino-4-hydroxivalerylderivat.
CA1309555C (en) * 1986-02-27 1992-10-27 Upjohn Company (The) Inhibiting peptides having a dihydroxyethylene isostere transitionstate insert
US4705846A (en) * 1986-03-27 1987-11-10 The Upjohn Company Novel renin inhibiting peptides having a gamma lactam pseudo dipeptide insert
US4743584A (en) * 1986-10-07 1988-05-10 Merck & Co., Inc. C-terminal amide cyclic renin inhibitors containing peptide isosteres
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US4743585A (en) * 1986-11-21 1988-05-10 Warner-Lambert Company Renin inhibitors
US4758584A (en) * 1987-02-05 1988-07-19 Ciba-Geigy Corporation Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
US5162497A (en) * 1987-09-24 1992-11-10 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
ATE107658T1 (de) * 1988-01-26 1994-07-15 Sankyo Co Renin inhibierende polypeptide, ihre herstellung und anwendung.
AU3428089A (en) * 1988-03-25 1989-10-16 The Administrators Of The Tulane Eductional Fund Therapeutic peptides
IL90872A0 (en) * 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
US5688770A (en) * 1989-12-14 1997-11-18 Schering Corporation Antiglaucoma compositions and methods
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6239273B1 (en) 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
AU2610000A (en) 1999-01-12 2000-08-01 Cambridge University Technical Services Limited Compounds and methods to inhibit or augment an inflammatory response
US6682739B1 (en) 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US7041465B1 (en) 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
KR20040096554A (ko) 2002-02-06 2004-11-16 비코르 테크놀로지스 인코포레이티드 경색방지 분자
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2536357A1 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2005056608A1 (en) 2003-12-04 2005-06-23 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
WO2005086800A2 (en) 2004-03-04 2005-09-22 Vanderbilt University Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
EP1750745A1 (en) 2004-05-11 2007-02-14 The United States of America, represented by the Secretary, Department of Health and Human Services Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
WO2006108270A1 (en) 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
ES2431315T3 (es) 2005-05-19 2013-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Epítopos funcionales del antígeno PsaA de Streptococcus pneumoniae y usos de los mismos
EP3467096B1 (en) 2005-06-07 2022-01-12 DSM Nutritional Products AG Eukaryotic microorganisms for producing lipids and antioxidants
PL2439268T3 (pl) 2005-06-16 2016-06-30 Dsm Nutritional Products Ag Immobilizowane enzymy i sposoby ich stosowania
US20100041597A1 (en) 2005-08-05 2010-02-18 Jenny Phipps Peptides targeted to protein kinase c isoforms and uses thereof
CN101378772B (zh) 2005-08-05 2013-12-04 阿拉伊姆药品公司 组织保护性肽及其用途
JP5178520B2 (ja) 2005-09-22 2013-04-10 メディバス エルエルシー 固体ポリマー送達組成物およびその使用法
EP1926780B1 (en) 2005-09-22 2013-08-14 Medivas, LLC Bis-( -amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
RU2507213C2 (ru) 2005-10-04 2014-02-20 Солидженикс, Инк., Новые пептиды для лечения и профилактики иммунопатологических заболеваний, включая лечение и профилактику инфекции посредством модулирования врожденного иммунитета
EP2392646A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
EP1945261A4 (en) 2005-11-07 2010-05-12 Scripps Research Inst COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
WO2007120265A2 (en) 2005-11-14 2007-10-25 Applera Corporation Coded molecules for detecting target analytes
CA2630559A1 (en) 2005-11-21 2007-05-24 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
ES2431526T3 (es) 2005-12-29 2013-11-26 The Regents Of The University Of California Office Of Technology Transfer Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2
CA2638911C (en) 2006-02-06 2018-01-23 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8865398B2 (en) 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
CA2664189C (en) 2006-09-21 2017-11-21 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
US8637459B2 (en) 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
WO2008085794A2 (en) 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
US20120030779A1 (en) 2007-01-18 2012-02-02 University Of Utah Research Foundtion Compositions and methods for detecting, treating, or preventing reductive stress
US8097588B2 (en) 2007-02-08 2012-01-17 Sanford-Burnham Medical Research Institute Trophinin-binding peptides and uses thereof
US9381226B2 (en) 2007-02-08 2016-07-05 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009023306A2 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
PL2245056T4 (pl) 2008-01-22 2016-01-29 Araim Pharmaceuticals Inc Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
US8841440B2 (en) 2008-04-01 2014-09-23 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
JP2011522540A (ja) 2008-06-04 2011-08-04 セルラー ダイナミクス インターナショナル， インコーポレイテッド 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
EP3045123B1 (en) 2008-06-16 2020-04-08 University Of Rochester Compositions comprising a combination of fibroblast growth factor (fgf) analogs with thrombopoietin for use for treating acute radiation syndrome
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
EP2396017B1 (en) 2009-02-16 2015-07-01 Cerenis Therapeutics Holding SA Apolipoprotein a-i mimics
CA2952805C (en) 2009-06-05 2021-06-01 Cellular Dynamics International, Inc. Reprogramming t cells and hematopoietic cells
BRPI1015424B1 (pt) 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US8409603B2 (en) 2009-10-01 2013-04-02 University Of South Carolina Compositions and methods for tissue engineering, tissue regeneration and wound healing
CN102725639A (zh) 2009-11-04 2012-10-10 诺华有限公司 蛋白质聚集物与单体分离中作为结合试剂的带正电物质
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
EP2499159B1 (en) 2009-11-13 2017-01-04 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
IT1397901B1 (it) 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
EP2552947A4 (en) 2010-03-26 2013-11-13 Dartmouth College VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
EP2691105B1 (en) 2011-03-28 2018-07-11 University of Utah Research Foundation Methods and compositions related to inhibition of viral entry
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
KR20140059249A (ko) 2011-08-30 2014-05-15 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 나트륨이뇨 폴리펩티드
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
MX347229B (es) 2012-01-26 2017-04-19 Christopher J Soares Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
WO2013154771A1 (en) 2012-04-12 2013-10-17 Georgia Regents University Redox-resistant nitric oxide synthase
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
TWI705073B (zh) 2012-06-22 2020-09-21 達特茅斯學院基金會 新穎之vista-ig構築體及vista-ig用於治療自體免疫、過敏及發炎病症之用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP3613765B1 (en) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
BR112015022624A2 (pt) 2013-03-14 2017-10-31 Uab Research Foundation regime de dose, e, método para tratamento de aterosclerose
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
AU2014296288B2 (en) 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
IL291922B1 (en) 2014-06-13 2026-01-01 Tufts College FAP-activated medical materials and related uses
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
WO2016022610A1 (en) 2014-08-06 2016-02-11 Vascular Biosciences Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same
US10189878B2 (en) 2014-09-24 2019-01-29 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
EP3226900A4 (en) 2014-12-05 2018-09-19 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
US11220545B2 (en) 2014-12-08 2022-01-11 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
US10765754B2 (en) 2015-08-28 2020-09-08 Navigen, Inc. Compositions and methods related to inhibition of respiratory syncytial virus entry
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017083700A1 (en) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
AU2017234528B2 (en) 2016-03-16 2023-09-28 Nathan Bartlett Neutralizing monoclonal antibodies to IL-25 and uses thereof
AU2017250191A1 (en) 2016-04-13 2018-11-08 Orimabs Ltd. Anti-PSMA antibodies and use thereof
US11649283B2 (en) 2016-04-15 2023-05-16 Immunext, Inc. Anti-human vista antibodies and use thereof
ES2965087T3 (es) 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
WO2018053180A2 (en) 2016-09-14 2018-03-22 The Trustees Of The University Of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
ES3037586T3 (en) 2016-11-09 2025-10-03 Mayo Found Medical Education & Res Manp analogues
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1
EP3759125A4 (en) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS
EP3773658A4 (en) 2018-04-06 2022-04-27 Dana-Farber Cancer Institute, Inc. KIR3DL3 AS HLA2 RECEPTOR, ANTI-HHLA2 ANTIBODY AND ITS USES
WO2020036646A2 (en) 2018-04-25 2020-02-20 The Methodist Hospital System Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
AU2019271366B2 (en) 2018-05-16 2026-02-26 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
WO2019234057A1 (en) 2018-06-05 2019-12-12 Dsm Ip Assets B.V. Process for the production of diglycerides
US20220118054A1 (en) 2018-11-09 2022-04-21 Mayo Foundation For Medical Education And Research Combination treatment for resistant hypertension
EP3986555A4 (en) 2019-06-19 2023-06-28 The Research Foundation for The State University of New York Methods for treating neointimal hyperplasia using f11r/jam-a inhibitors
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
EP4440594A2 (en) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1585061A (en) 1977-03-15 1981-02-25 Nat Res Dev Synthesis of peptides
US4198398A (en) 1977-07-12 1980-04-15 Derek Hudson Enkephalin analogues

Also Published As

Publication number Publication date
FI812427A7 (fi) 1982-02-07
AU549157B2 (en) 1986-01-16
IE811785L (en) 1982-02-06
DE3172138D1 (en) 1985-10-10
NO812612L (no) 1982-02-08
IE51471B1 (en) 1986-12-24
ES8305306A1 (es) 1983-04-01
FI812427L (fi) 1982-02-07
US4424207A (en) 1984-01-03
EP0045665A1 (en) 1982-02-10
ES504575A0 (es) 1983-04-01
AU7381581A (en) 1982-02-11
EP0045665B1 (en) 1985-09-04

Similar Documents

Publication Publication Date Title
DK349481A (da) Enzyminhibitorer
DK478684D0 (da) Enzyminhibitorer
FI810352L (fi) Beta-lactam-antibioter
FI812994L (fi) Dubbellagrig sikt foer en bladbildningsdel i en pappersmaskin
FI811271L (fi) Skrovuppvaermningssystem foer en offshore-produktionsstruktur foer anvaendning i arktiska vatten
FI813156L (fi) Stabila detergentsuspensioner i vaetskeform
BR8104796A (pt) Fiadeira
FI811624L (fi) Kolv i synnerhet foer foerbraenningsmotor
FI812934L (fi) Braennare foer montering i vaermnings- och aongpanna
FI810452L (fi) Viskos flytande tvaolsammansaettning
FI810671L (fi) Laepplist foer inloppslaoda i pappersmaskin
FI804052L (fi) Baerarband i dragkedja foer trikao
FI813718L (fi) Rulldrivanordning foer glasskivetransportoer i boejningssystem
FI813549L (fi) Doseringsask foer tabletter
FI821353A0 (fi) Solvaermesystem i byggnad
FI813274L (fi) I vaerme vidhaeftande elastisk traod
AT383235B (de) Verstaerker
FI813914L (fi) Beskicknings- och toemningsanordning foer hyllbottnar i maelterier
FI811473L (fi) Modulatorer foer immunsystem
FI802838A7 (fi) Omkastningsmekanism foer rotationsriktningen i en borrningsapparat
FI810892L (fi) Foerbindning foer maongriktningslaenkar foer staenger i olika baerstrukturer
DK59980A (da) Drejeaktivator
FI811150L (fi) Sikttrumma foer sorterare i pappersindustri
FI812353L (fi) Saekring foer muffoerband i plastroer
SE8100393L (sv) Plasminogenpreparat

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment